Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Therapeutics Receives Notification of PDUFA Extension for Eteplirsen

Business Wire February 8, 2016

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 2, 2016

Structural Volatility Won't End For Several Years, Derivatives Strategist Says

Benzinga.com  January 27, 2016

Bragar Eagel & Squire, P.C. Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT) on Behalf of Stockholders and Encourages Investors to Contact the Firm

Business Wire January 26, 2016

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Sarepta Therapeutics, Inc. and Advises Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire January 24, 2016

Lifshitz & Miller Law Firm Announces Investigation of GoPro Inc., Iconix Brand Group, Inland Real Estate Corporation, Nobilis Health Corp., Sarepta Therapeutics, Inc., Synutra International Inc., and Wilshire Bancorp Inc.

PR Newswire January 22, 2016

INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Sarepta Therapeutics, Inc. and Strongly Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire January 20, 2016

FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C. Area

Business Wire January 20, 2016

Wolf Popper LLP Announces Investigation of Fraud Claims on Behalf of Investors in Sarepta Therapeutics, Inc.

PR Newswire January 19, 2016

IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of Claims Against Sarepta Therapeutics, Inc. and Strongly Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire January 16, 2016

SHAREHOLDER ALERT: Abraham, Fruchter & Twersky, LLP Announces An Investigation of Sarepta Therapeutics, Inc. (SRPT)

Business Wire January 15, 2016

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launch Investigation of Sarepta Therapeutics, Inc. for Possible Breaches of Fiduciary Duty

Business Wire January 15, 2016

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Sarepta Therapeutics, Inc. - SRPT

PR Newswire January 15, 2016

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sarepta Therapeutics Inc. (SRPT)

PR Newswire January 15, 2016

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 4, 2016

Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Business Wire December 18, 2015

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 1, 2015

Sarepta Therapeutics Announces Publication of Positive Long-Term Safety and Efficacy Data for Eteplirsen in the Annals of Neurology

Business Wire November 17, 2015

Sarepta Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Developments

Business Wire November 5, 2015

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 30, 2015